Cover Image
Market Research Report

Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence - Global Forecast to 2027

Published by Meticulous Market Research Pvt. Ltd. Product code 924500
Published Content info 231 Pages
Delivery time: 1-2 business days
Price
Back to Top
Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence - Global Forecast to 2027
Published: February 11, 2020 Content info: 231 Pages
Description

Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Forecast to 2027

The global vaccines market is expected to grow at a CAGR of 5.2% from 2019 to 2027 to reach $62.2 billion by 2027.

The growth in the global vaccines market is mainly attributed to high prevalence of various diseases, increasing government initiatives towards immunization, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials, growing focus on therapeutic vaccines, and emerging markets will further provide significant opportunities for the various stakeholders in this market. However, longer timelines and high cost for vaccines development are likely to hinder the market growth.

On the basis of indication, the pneumococcal disease segment commanded the largest share of the overall vaccines market in 2019. The large share of this segment is mainly attributed to the factors such as rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and various initiatives by the government organizations and private sectors to prevent and control outbreak of pneumococcal diseases.

On the basis of valence, multivalent vaccines segment accounted for the largest share of the overall vaccines market in 2019 and is poised to grow at a faster CAGR during the forecast period. New product launches and focus of key players on multivalent vaccine' research & development are the major factors contributing to the largest share and fastest CAGR of multivalent vaccines market segment.

On the basis of antigen, subunit and conjugate vaccines segment accounted for the largest share of this market in 2019 due to long term immunity and low-risk rate associated with the subunit vaccines along with the increasing demand for immunization.

An in-depth analysis of the geographical scenario of the vaccines market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global vaccines market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The large share of this region is mainly attributed to the factors such as availability of new technologies, increasing immunization programs, presence of key players, and growing investments in the establishment of vaccine manufacturing facilities in the region.

The key players operating in the global vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca (U.K.).

Scope of the Report:

Global Vaccines Market, by Indication

  • Pneumococcal Disease
  • Influenza
  • DTP
  • Human Papilloma Virus (HPV)
  • Meningococcal Disease
  • Poliomyelitis (Polio)
  • MMR
  • Rotavirus
  • Hepatitis
  • Other Indications

Note: Other indications include varicella, herpes zoster vaccines, chlorella, and rabies vaccines.

Global Vaccines Market, by Route of Administration

  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Oral
  • Other Routes

Note: Other routes include intradermal (ID), transcutaneous (TC), and nasal route

Global Vaccines Market, by Type/Antigen

  • Subunit & Conjugate Vaccines
  • Inactivated vaccines
  • Live Attenuated Vaccines
  • Toxoid vaccines
  • Combination Vaccines

Global Vaccines Market, by Valence

  • Multivalent Vaccines
  • Monovalent vaccines

Global Vaccines Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa
Table of Contents

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency
  • 1.4. Key Stakeholders

2 Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Strong Vaccines Pipeline
    • 4.2.2. Rising Adoption of Vaccination
    • 4.2.3. Increasing Government Focus on Immunization Programs
    • 4.2.4. Technological Progress in Vaccine Administration
  • 4.3. Restraints
    • 4.3.1. High Cost Associated with Vaccine Development
    • 4.3.2. Longer Timelines for Vaccine Manufacturing
  • 4.4. Opportunities
    • 4.4.1. Increasing Epidemic Potentials
    • 4.4.2. Growing Focus on Therapeutic Vaccines
    • 4.4.3. Growth Prospects in Emerging Markets
    • 4.4.4. Increasing Use of Adjuvants in Vaccines
  • 4.5. Challenges
    • 4.5.1. Product Recalls
    • 4.5.2. Inadequate Access to Vaccines

5. Industry Analysis

  • 5.1. Regulatory Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Unmet Needs Analysis
  • 5.4. Pricing Analysis, by Region

6. Global Vaccines Market, by Indication

  • 6.1. Introduction
  • 6.2. Pneumococcal Disease
  • 6.3. Influenza
  • 6.4. Human Papilloma Virus (HPV)
  • 6.5. DTP
  • 6.6. Meningococcal Disease
  • 6.7. MMR
  • 6.8. Rotavirus
  • 6.9. Poliomyelitis (Polio)
  • 6.10. Hepatitis
  • 6.11. Other Indications

7. Global Vaccines Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular (IM)
  • 7.3. Subcutaneous (SC)
  • 7.4. Oral
  • 7.5. Other (Routes of Administration)

8. Global Vaccines Market, by Type/Antigen

  • 8.1. Introduction
  • 8.2. Subunit & Conjugate Vaccines
  • 8.3. Inactivated Vaccines
  • 8.4. Live Attenuated Vaccines
  • 8.5. Toxoid Vaccines
  • 8.6. Combination Vaccines

9. Global Vaccines Market, by Valence

  • 9.1. Introduction
  • 9.2. Multivalent Vaccines
  • 9.3. Monovalent Vaccines

10. Global Vaccines Market, by Geography

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Asia Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. India
    • 10.4.4. Rest of Asia Pacific
  • 10.5. Latin America
  • 10.6. Middle East & Africa

11. Competitive Landscape

  • 11.1. Introduction
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Market Share Analysis
    • 11.4.1. Market Share Analysis, by Company
    • 11.4.2. Market Share Analysis, by Product

12. Company Profiles

  • 12.1. Sanofi
    • 12.1.1. Business Overview
    • 12.1.2. Financial Overview
    • 12.1.3. Product Portfolio
    • 12.1.4. Pipeline Products
    • 12.1.5. Strategic Developments
  • 12.2. Merck & Co., Inc.
    • 12.2.1. Business Overview
    • 12.2.2. Financial Overview
    • 12.2.3. Product Portfolio
    • 12.2.4. Pipeline Products
    • 12.2.5. Strategic Developments
  • 12.3. GlaxoSmithKline Plc.
    • 12.3.1. Business Overview
    • 12.3.2. Financial Overview
    • 12.3.3. Product Portfolio
    • 12.3.4. Pipeline Products
    • 12.3.5. Strategic Developments
  • 12.4. Pfizer, Inc.
    • 12.4.1. Business Overview
    • 12.4.2. Financial Overview
    • 12.4.3. Product Portfolio
    • 12.4.4. Pipeline Products
    • 12.4.5. Strategic Developments
  • 12.5. Johnson & Johnson
    • 12.5.1. Business Overview
    • 12.5.2. Financial Overview
    • 12.5.3. Product Portfolio
    • 12.5.4. Pipeline Products
    • 12.5.5. Strategic Developments
  • 12.6. Daiichi Sankyo Co., Ltd.
    • 12.6.1. Business Overview
    • 12.6.2. Financial Overview
    • 12.6.3. Product Portfolio
    • 12.6.4. Pipeline Products
  • 12.7. Takeda Pharmaceutical Company Limited
    • 12.7.1. Business Overview
    • 12.7.2. Financial Overview
    • 12.7.3. Product Portfolio
    • 12.7.4. Pipeline Products
    • 12.7.5. Strategic Developments
  • 12.8. CSL Limited
    • 12.8.1. Business Overview
    • 12.8.2. Financial Overview
    • 12.8.3. Product Portfolio
    • 12.8.4. Pipeline Products
    • 12.8.5. Strategic Developments
  • 12.9. Emergent BioSolutions Inc.
    • 12.9.1. Business Overview
    • 12.9.2. Financial Overview
    • 12.9.3. Product Portfolio
    • 12.9.4. Pipeline Products
    • 12.9.5. Strategic Developments
  • 12.10. AstraZeneca

12.10.1.Business Overview

12.10.2.Financial Overview

12.10.3.Product Portfolio

12.10.4.Pipeline Products

13. Appendix

  • 13.1. Questionnaire
  • 13.2. Available Customization

List of Tables

  • Table 1 Global Vaccines Market Drivers: Impact Analysis (2019-2025)
  • Table 2 Key Government Regulatory Agencies
  • Table 3 List of Some of the Promising Vaccines in the Pipeline
  • Table 4 ASP of Key Vaccines, by Region ($ Per Unit)
  • Table 5 Global Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 6 Overview: Pneumococcal Disease
  • Table 7 Pneumococcal Diseases: Pipelined Vaccines
  • Table 8 Key Companies offering Pneumococcal Vaccines
  • Table 9 Pneumococcal Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 10 Overview: influenza Disease
  • Table 11 Influenza Diseases: Pipelined Vaccines
  • Table 12 Key Companies offering influenza Vaccines
  • Table 13 Influenza Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 14 Overview: HPV Disease
  • Table 15 HPV Vaccine Cost (2017)
  • Table 16 Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 17 Overview: Diphtheria, Tetanus, Pertussis Disease
  • Table 18 Global Supply of D&T by Product Group
  • Table 19 Key Companies offering DTP Vaccines
  • Table 20 DTP Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 21 Overview: Meningococcal Disease
  • Table 22 Marketed Meningococcal Vaccine Combinations
  • Table 23 Key Companies offering Meningococcal Vaccines
  • Table 24 Meningococcal Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 25 Overview: Measles, Mumps and Rubella Disease
  • Table 26 Key Companies offering MMR Vaccines
  • Table 27 MMR Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 28 Overview: Rotavirus Disease
  • Table 29 Key Companies offering Rotavirus Vaccines
  • Table 30 Rotavirus Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 31 Overview: Poliomyelitis Disease
  • Table 32 Polio Cases and Endemic Countries
  • Table 33 Key Companies offering Polio Vaccines
  • Table 34 Polio Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 35 Overview: Hepatitis A
  • Table 36 Overview: Hepatitis B
  • Table 37 Key Companies offering Hepatitis Vaccines
  • Table 38 Hepatitis Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 39 Other Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 40 Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 41 Intramuscular Sites of Vaccine Administration, by Age Group
  • Table 42 Vaccines for intramuscular Administration
  • Table 43 Key Companies offering intramuscular Vaccines
  • Table 44 Intramuscular Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 45 Site of Administration of Subcutaneous Vaccines by Age Group
  • Table 46 Vaccines for Subcutaneous Administration
  • Table 47 Key Companies offering Subcutaneous Vaccines
  • Table 48 Subcutaneous Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 49 Key Companies offering Oral Vaccines
  • Table 50 Oral Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 51 Other (Route of Administration) Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 52 Types of Vaccines, by Antigen
  • Table 53 Global Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 54 Companies offering Subunit & Conjugate Vaccines
  • Table 55 Subunit & Conjugate Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 56 Companies Offering Inactivated Vaccines
  • Table 57 Inactivated Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 58 Companies Offering Live Attenuated Vaccines
  • Table 59 Live Attenuated Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 60 Toxoid Vaccines Used in the Vaccination Schedule
  • Table 61 Companies Offering Toxoid Vaccines
  • Table 62 Toxoid Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 63 Companies offering Combination Vaccines
  • Table 64 Combination Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 65 Global Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 66 Available Multivalent Vaccines for Children
  • Table 67 Companies offering Multivalent Vaccines
  • Table 68 Multivalent Vaccines Market Size, by Region/Country, 2016-2025 ($Million)
  • Table 69 Malaria, Ebola and Dengue Disease Vaccines in Pipeline
  • Table 70 Companies offering Monovalent Vaccines
  • Table 71 Monovalent Vaccines Market Size, by Region/Country, 2017-2027 ($Million)
  • Table 72 Global Vaccines Market Size, by Country/ Region, 2017-2027 ($Million)
  • Table 73 North America: Vaccines Market Size, by Country, 2017-2027 ($Million)
  • Table 74 North America: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 75 North America: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 76 North America: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 77 North America: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 78 Influenza Burden in the U.S., 2012-2018
  • Table 79 Pfizer Inc. Vaccine Pipeline in the U.S.
  • Table 80 U.S.: Macroindicators
  • Table 81 U.S.: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 82 U.S.: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 83 U.S.: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 84 U.S.: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 85 Canada: Macroindicators
  • Table 86 Canada: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 87 Canada: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 88 Canada: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 89 Canada: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 90 Europe: Vaccines Market Size, by Country, 2017-2027 ($Million)
  • Table 91 Europe: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 92 Europe: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 93 Europe: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 94 Europe: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 95 Germany: Macroindicators
  • Table 96 Germany: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 97 Germany: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 98 Germany: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 99 Germany: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 100 U.K.: Macroindicators
  • Table 101 U.K.: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 102 U.K.: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 103 U.K.: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 104 U.K.: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 105 France: Macroindicators
  • Table 106 France: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 107 France: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 108 France: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 109 France: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 110 Italy: Macroindicators
  • Table 111 Italy: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 112 Italy: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 113 Italy: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 114 Italy: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 115 Spain: Macroindicators
  • Table 116 Spain: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 117 Spain: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 118 Spain: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 119 Spain: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 120 RoE: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 121 RoE: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 122 RoE: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 123 RoE: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 124 Asia-Pacific: Vaccines Market Size, by Country, 2017-2027 ($Million)
  • Table 125 Asia-Pacific: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 126 Asia-Pacific: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 127 Asia-Pacific: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 128 Asia-Pacific: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 129 Japan: Macroindicators
  • Table 130 Japan: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 131 Japan: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 132 Japan: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 133 Japan: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 134 China: Macroindicators
  • Table 135 China: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 136 China: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 137 China: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 138 China: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 139 Cost of Some of the Vaccines in India
  • Table 140 India: Macroindicators
  • Table 141 India: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 142 India: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 143 India: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 144 India: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 145 RoAPAC: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 146 RoAPAC: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 147 RoAPAC: Vaccines Market Size, by Type, 2017-2027 ($Million)
  • Table 148 RoAPAC: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 149 Latin America: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 150 Latin America: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 151 Latin America: Vaccines Market Size, by Type, 2016-2025 ($Million)
  • Table 152 Latin America: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 153 Middle East & Africa: Vaccines Market Size, by indication, 2017-2027 ($Million)
  • Table 154 Middle East & Africa: Vaccines Market Size, by Route of Administration, 2017-2027 ($Million)
  • Table 155 Middle East & Africa: Vaccines Market Size, by Type, 2016-2025 ($Million)
  • Table 156 Middle East & Africa: Vaccines Market Size, by Valence, 2017-2027 ($Million)
  • Table 157 Number of Developments by the Major Players During 2016-2019
  • Table 158 Vaccines Market: Product Competitive Benchmarking
  • Table 159 Vaccines Market: Geographic Competitive Benchmarking

List of Figures

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives interviewed
  • Figure 5 Breakdown of Primary interviews (Supply Side & Demand Side)
  • Figure 6 Market Sizing and Growth forecast Approach
  • Figure 7 Global Vaccines Market, by indication, 2019-2027 ($Million)
  • Figure 8 Global Vaccines Market Size, by Route of Administration, 2019-2027 ($Million)
  • Figure 9 Global Vaccines Market Size, by Antigen/Type, 2019-2027 ($Million)
  • Figure 10 Multivalent Vaccine Segment Will Dominate the Global Vaccines Market During the forecast Period
  • Figure 11 Vaccines Market, by Region
  • Figure 12 Products in Pipeline for infectious Diseases: 2018
  • Figure 13 Vaccines Projects in Pipeline: 2017
  • Figure 14 Disposable income Per Capita of China (in $): 2014-2018
  • Figure 15 Global Vaccination Coverage for Tuberculosis, Hepatitis B, and Rotavirus: 2010-2018
  • Figure 16 Decrease in Number of Tuberculosis Deaths: 2012-2017
  • Figure 17 Therapeutic Vaccines in Pipeline for Cancer: 2011 and 2018
  • Figure 18 New Cancer Cases in Asia, Latin America and Caribbean: 2018-2040
  • Figure 19 Vaccines Market, Product Pipeline, by Phase (2018)
  • Figure 20 Global Vaccines Market Size, by indication, 2019-2027 ($Million)
  • Figure 21 Influenza Vaccines Distribution: 2016-2019
  • Figure 22 Forecasted Global Demand of DTwP Vaccines: 2018-2032
  • Figure 23 MMR Vaccines Supply: 2016-2018
  • Figure 24 Global Vaccination Coverage for Rotavirus: 2010-2018
  • Figure 25 U.S. Funding for Global Polio: 2013-2019
  • Figure 26 Different Routes of Vaccine Administration
  • Figure 27 Vaccines Market Size, by Route of Administration, 2019-2027 ($Million)
  • Figure 28 Global Vaccines Market Size, by Type, 2019-2027 ($Million)
  • Figure 29 Global Vaccines Market Size, by Valence, 2019-2027 ($Million)
  • Figure 30 Global Vaccines Size, by Region, 2019-2027 ($Million)
  • Figure 31 North America: Vaccines Market Size, by Country, 2019-2027 ($Million)
  • Figure 32 U.S. Funding for Global Polio: 2013-2019
  • Figure 33 Europe: Vaccines Market Size, by Country, 2019-2027 ($Million)
  • Figure 34 Increase in Immunization After Mandatory Vaccination
  • Figure 35 Increase in Number of Registered influenza Cases (2015-2019)
  • Figure 36 Spain: increase in Number of Biotechnology Companies (2010-2016)
  • Figure 37 Asia-Pacific: Vaccines Market Size, by Country, 2019-2027 ($Million)
  • Figure 38 India: Increasing Health Expenditure (2010-2018)
  • Figure 39 Cancer incidence in Middle East and Africa: 2012 and 2030
  • Figure 40 Key Growth Strategies Adopted by Leading Players -2016-2019
  • Figure 41 Global Vaccines Market Share, by Key Players, 2018 (%)
  • Figure 42 Vaccines Market Share Analysis, by Brand (2018)
  • Figure 43 Sanofi: Financial Overview (2016-2018)
  • Figure 44 Merck & Co., Inc.: Financial Overview (2016-2018)
  • Figure 45 GlaxoSmithKline Plc (GSK): Financial Overview (2016-2018)
  • Figure 46 Pfizer Inc.: Financial Overview (2016-2018)
  • Figure 47 Johnson & Johnson (J&J): Financial Overview (2016-2018)
  • Figure 48 Daichi Sankyo Co., Ltd.: Financial Overview (2016-2018)
  • Figure 49 Takeda Pharmaceutical: Financial Overview (2017-2019)
  • Figure 50 CSL Limited: Financial Overview (2017-2019)
  • Figure 51 Emergent BioSolutions Inc.: Financial Overview (2016-2018)
  • Figure 52 AstraZeneca: Financial Overview (2016-2018)
Back to Top